Secondary analysis of the ALPINE trial in relapsed/refractory CLL/SLL: zanubrutinib vs ibrutinib had less recurrent symptom deterioration and a 28–33% lower risk of progression or death after adjusting for patient-reported symptom scores.
Secondary analysis
Victor et al. Association between patient-reported symptoms and clinical outcomes in R/R CLL